Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Crawford’s FDA Confirmation Woes Grow With Sen. Coburn’s Threatened Hold

This article was originally published in The Pink Sheet Daily

Executive Summary

The Oklahoma Republican says he will place a hold on FDA Commissioner nominee Crawford because the agency has not finalized condom labeling rules. Coburn joins a list of Democrats who are also threatening to place a hold on Crawford’s nomination.

You may also be interested in...



FDA's Plan B OTC Switch Decision Deadline Is Sept. 1, HHS' Leavitt Says

Sens. Clinton and Murray lift their hold on FDA Acting Commissioner Crawford's nomination after a letter from HHS secretary says FDA action on Barr's Rx-to-OTC switch application is imminent.

FDA's Plan B OTC Switch Decision Deadline Is Sept. 1, HHS' Leavitt Says

Sens. Clinton and Murray lift their hold on FDA Acting Commissioner Crawford's nomination after a letter from HHS secretary says FDA action on Barr's Rx-to-OTC switch application is imminent.

Next Round For Commissioner Nominee: Crawford Placed On Hold After Clearing Senate Health Committee

The nomination of Acting Commissioner Crawford to the permanent FDA post passed the committee. A full Senate vote will be delayed by a long-anticipated hold placed by Sens. Murray and Clinton, who demand the agency first make a decision on the OTC switch of Barr's Plan B emergency contraceptive.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS062200

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel